Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Sorafenib in Advanced Hepatocellular Carcinoma

정, 재. (2008) · Cited by 5,586

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,725

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756

Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor

Li, P., Qin, P., Fu, X., Zhang, G., Yan, X., Zhang, M., Zhang, X., Yang, J., Wang, H., & Ma, Z. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-163 · Cited by 44

Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma

Xia, Y., Wei, J., Zhao, S., Guo, B., Meng, F., Klumperman, B., & Zhong, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.032 · Cited by 44

A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy

Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 44

Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development

Li, X., Wang, Y., Ye, X., & Liang, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635243 · Cited by 43

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

Yuan, G., Cheng, X., Li, Q., Zang, M., Huang, W. M., Fan, W., Wu, T., Ruan, J., Dai, W., Yu, W., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s286169 · Cited by 42

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

Cousin, S., Guégan, J., Shitara, K., Palmieri, L., Guégan, J., Pernot, S., Fukuoka, S., Koyama, S., Nishikawa, H., Bellera, C. A., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02092-x · Cited by 42

Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study

Zhou, N., Jiang, M., Li, T., Zhu, J., Liu, K., Hou, H., & Zhang, X. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.006 · Cited by 41

Advances in targeted therapy and immunotherapy for esophageal cancer

Yang, H., Li, X., & Yang, W. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002768 · Cited by 41

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

Xia, L., Peng, J., Lou, G., Pan, M., Zhou, Q., Hu, W., Shi, H., Wang, L., Gao, Y., Zhu, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003831 · Cited by 37

Integrated immune gene expression signature and molecular classification in gastric cancer: New insights

Refolo, M. G., Lotesoriere, C., Messa, C., Caruso, M. G., & D’Alessandro, R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0120-221r · Cited by 38

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

Lickliter, J. D., Gan, H. K., Voskoboynik, M., Arulananda, S., Gao, B., Nagrial, A. M., Grimison, P., Harrison, M., Zou, J., Zhang, L., et al. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s243787 · Cited by 37

Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?

Lai, E., Astara, G., Ziranu, P., Pretta, A., Migliari, M., Dubois, M., Donisi, C., Mariani, S., Liscia, N., Impera, V., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103167 · Cited by 35

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Huang, S.-L., Wang, Y., Wang, Q.-Y., Feng, G.-G., Wu, F., Yang, L., Zhang, X.-H., & Xin, H.-W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.691391 · Cited by 37

Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma

Muhammed, A., D’Alessio, A., Enica, A., TALBOT, T. L., Fulgenzi, C. A. M., Nteliopoulos, G., Goldin, R. D., Cortellini, A., & Pinato, D. J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049244 · Cited by 35

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma

Mao, L., Lian, B., Li, C., Bai, X. L., Zhou, L., Cui, C., Chi, Z., Sheng, X., Wang, X., Tang, B., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1363 · Cited by 37

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

Yang, J., He, X., Lv, Q., Jing, J., & Shi, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00726 · Cited by 36

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives

Zhang, Z., Xie, T., Zhang, X., Qi, C., Shen, L., & Peng, Z. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.03.02 · Cited by 36

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis

Qin, J., Huang, Y., Zhou, H., & Yi, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807102 · Cited by 35

Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis

Bu, J., Jeong, W.-J., Jafari, R., Kubiatowicz, L. J., Nair, A., Poellmann, M. J., Hong, R. S., Liu, E. W., Owen, R. H., Rawding, P. A., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114445 · Cited by 35

Novel immunotherapeutic approaches for hepatocellular carcinoma treatment

Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 36

Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial.

Ren, C., Mai, Z.-J., Jin, Y., He, M.-M., Wang, Z., Luo, H., Zhang, D., Wu, C.-Y., Wang, F., & Xu, R. (2020) · PubMed Central · Cited by 35

Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma

Xie, F., Bai, Y., Yang, X., Long, J., Mao, J., Lin, J., Wang, D., Song, Y., Xun, Z., Huang, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107135 · Cited by 37

Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer

Chen, Y., Bai, B., Ying, K., Pan, H., & Xie, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188775 · Cited by 36

circDNMT1 Promotes Malignant Progression of Gastric Cancer Through Targeting miR-576-3p/Hypoxia Inducible Factor-1 Alpha Axis

Li, H., Cao, B., Zhao, R., Li, T., Xu, X., Cui, H., Deng, H., Gao, J., & Wei, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817192 · Cited by 36

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma

Ji, J. H., Ha, S. Y., Lee, D., Sankar, K. N., Koltsova, E. K., Abou‐Alfa, G. K., & Yang, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087640 · Cited by 34

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives

Lin, N., Song, Y., & Zhu, J. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.03.03 · Cited by 34

Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives

Girardi, D. M., Sousa, L. P., Miranda, T. A., Haum, F. N. C., Pereira, G. C. D. B., & Pereira, A. A. L. (2023) · Cancers · doi:10.3390/cancers15061680 · Cited by 35

Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis

Wang, B., Zhang, Z., Liu, W., & Tan, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114180 · Cited by 38

Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications

Zhou, Y., Zhu, G., Lu, X., Zheng, K. I., Wang, Q.-W., Chen, J.-N., Zhang, Q., Yan, F., & Li, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02525-8 · Cited by 33

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Liu, H.-T., Jiang, M., Deng, Z., Li, L., Huang, J.-L., Liu, Z., Li, L., & Zhong, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737497 · Cited by 34

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Tang, Z., Wang, Y., Yu, Y., Cui, Y., Liang, L., Xu, C., Shen, Z., Shen, K., Wang, X., Liu, T., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02309-0 · Cited by 33

Immune-based combination therapy for esophageal cancer

Wang, H., Xu, Y., Zuo, F., Liu, J., & Yang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020290 · Cited by 33

Implications of driver genes associated with a high tumor mutation burden identified using next‑generation sequencing on immunotherapy in hepatocellular carcinoma

Li, L., Rao, X., Wen, Z., Ding, X., Wang, X., Xu, W., Meng, C., Yi, Y., Guan, Y., Chen, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11372 · Cited by 31

PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer

Chen, H., Jiang, T., Lin, F.-Y., Guan, H., Zheng, J., Liu, Q., Du, B., Huang, Y., & Lin, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107929 · Cited by 32

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial

Hou, Z., Zhu, K., Yang, X., Chen, P., Zhang, W., Cui, Y., Zhu, X., Song, T., Li, Q., Li, H., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2990 · Cited by 31

Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives

Girardi, D. M., Pacifico, J. P. M., de Amorim, F. P. L. G., Fernandes, G. D. S., Teixeira, M. C., & Pereira, A. A. L. (2020) · Pharmaceuticals · doi:10.3390/ph14010028 · Cited by 30

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Qu, Y., Sun, Z., Han, W., Zou, Q., Xing, N., Luo, H., Zhang, X., He, C., Bian, X., Cai, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004427 · Cited by 31

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

Chen, J., Zhang, D., & Yuan, Y. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00873-6 · Cited by 30

Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review

Shao, F., Zhang, H., Yang, X., Luo, X., & Liu, J. (2020) · Neoplasma · doi:10.4149/neo_2020_190801n701 · Cited by 30

Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors

Cho, R., Sakurai, Y., Jones, H. S., Akita, H., Hisaka, A., & Hatakeyama, H. (2020) · Cancers · doi:10.3390/cancers12123630 · Cited by 31

Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study

Huang, Y., Zhang, Z., Liao, W., Hu, K., & Wang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650394 · Cited by 29

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial

Wang, X., Wu, X., Yang, Y., Xu, W., Tian, H., Lian, B., Chi, Z., Si, L., Sheng, X., Kong, Y., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.027 · Cited by 30

An Overview of Cancer Biology, Pathophysiological Development and It’s Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy

Al-Ostoot, F. H., Salah, S., & Khanum, S. A. (2024) · Cancer Investigation · doi:10.1080/07357907.2024.2361295 · Cited by 30

Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma

Yang, Y., Wang, C., Sun, H., Jiang, Z., Zhang, Y. X., & Pan, Z. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0186-7 · Cited by 29

Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Qu, Y., Zhang, H., Guo, H., Luo, H., Zou, Q., Xing, N., Xia, S., Sun, Z., Zhang, X., He, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1698 · Cited by 27

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma

Wang, Y., Xu, X., Tang, J., Sun, Z.-Y., Fu, Y., Zhao, X., Ma, X., & Ye, Q. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00640-2 · Cited by 27

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

Yang, Z., Deng, W., Zhang, X., An, Y., Liu, Y., Yao, H., & Zhang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.789330 · Cited by 27

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma

Yang, F., Yang, J., Xiang, W., Zhong, B., Li, W.-C., Shen, J., Zhang, S., Yin, Y., Sun, H., Wang, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.657512 · Cited by 27

Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis

Wen, W., Zhang, Y., Zhang, H., & Chen, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04057-3 · Cited by 28

Targeting ferroptosis in hepatocellular carcinoma

Mo, Y., Zou, Z., & Chen, E. (2023) · Hepatology International · doi:10.1007/s12072-023-10593-y · Cited by 29

The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers

Starzer, A. M., Wolff, L., Popov, P., Kiesewetter, B., Preusser, M., & Berghoff, A. S. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102718 · Cited by 29

Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells

WANG, W., Wang, T., ZHANG, Y., Deng, T., ZHANG, H., & Ba, Y. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.046676 · Cited by 26

Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma

Zhu, Y., & Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.003 · Cited by 26

Research Progress of Immunotherapy for Gastric Cancer

Zhang, Z., Liu, N., & Sun, M. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221150555 · Cited by 26

The clinical application of camrelizumab on advanced hepatocellular carcinoma

Chen, Z., Lu, X., & Koral, K. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1807939 · Cited by 26

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study

Meng, X., Wang, J., Xia, J., Wu, T., Luo, Z., Hong, Y., Lu, P., Guo, Y., Ji, Y., Zhang, M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114328 · Cited by 25

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study

Wei, F., Huang, Q., He, J., Luo, L., & Zeng, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s304820 · Cited by 25

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer

Gao, G., Zhao, J., Ren, S., Wang, Y., Chen, G., Chen, J., Gu, K., Guo, R., Pan, Y., Wang, Q., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-4792 · Cited by 25

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

Zhang, L., Wang, W., Ge, S., Li, H., Bai, M., Duan, J., Yang, Y., Ning, T., Liu, R., Wang, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10661-4 · Cited by 25

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial

Hu, Y., Qin, T., Li, S., Zhang, T., & Xue, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01589 · Cited by 25

Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching

Tang, C., He, Q., Feng, J., Liao, Z., Peng, Y., & Gao, J. X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254158 · Cited by 24

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Liu, Z.-L., Liu, J., Staiculescu, D., & Chen, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018026 · Cited by 24

Targeting the Microenvironment in Esophageal Cancer

Wang, L., Han, H., Wang, Z., Shi, L., Yang, M., & Qin, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.684966 · Cited by 25

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

Chen, X., Wu, W., Wei, W., & Zou, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869488 · Cited by 24

Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions

Weinmann, A., & Galle, P. R. (2020) · Current Oncology · doi:10.3747/co.27.7315 · Cited by 25

Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma

Wong, M., Kim, J. T., Cox, B. K., Larson, B. K., Kim, S., Waters, K. M., Vail, E., & Guindi, M. M. (2021) · Hepatic Oncology · doi:10.2217/hep-2020-0034 · Cited by 22

Camrelizumab: an investigational agent for hepatocellular carcinoma

Xu, B., & Sun, H. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2022121 · Cited by 23

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22

Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis

Fan, W., Shen, L., Chen, S., Qiu, Z., Qi, H., Yuan, H., Cao, F., Xie, L., Chen, Q., & Li, W. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_801_19 · Cited by 22

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

He, S., Jiang, W., Fan, K., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626984 · Cited by 22

Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy

Pan, S., Yu, Y., Wang, S., Tu, B., Shen, Y., Qiu, Q., Liu, X., Su, N., Zuo, Y., Luan, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892618 · Cited by 22

The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review

Nakayama, I., & Takahari, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093226 · Cited by 22

Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer

Zhao, W., Qiu, L., Liu, H., Xu, Y., Zhan, M., Zhang, W., Xin, Y., He, X., Yang, X., Bai, J., et al. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-409 · Cited by 22

Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers

Xu, Q., & Shao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487610 · Cited by 24

Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma

Huang, D., Cui, P., Huang, Z., Wu, Z., Tao, H., Zhang, S., Xiang, R., & Hu, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03380-x · Cited by 21

Angiotensin-Converting Enzyme Inhibitors Have Adverse Effects in Anti-Angiogenesis Therapy for Hepatocellular Carcinoma

Zhang, S., Cao, M.-Q., Hou, Z., Gu, X.-Y., Chen, Y., Chen, L., Luo, Y., Chen, L.-W., Liu, D., Zhou, H.-Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.031 · Cited by 22

Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma

Li, L., Kan, X., Zhao, Y., Liang, B., Ye, T., Yang, L., & Zheng, C. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.55510 · Cited by 21

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

Yin, X., Wu, T., Lan, Y., & Yang, W. (2022) · Bioscience Reports · doi:10.1042/bsr20212304 · Cited by 22

Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review

Damaskos, C., Garmpis, N., Dimitroulis, D., Garmpi, A., Psilopatis, I., Sarantis, P., Koustas, E., Kanavidis, P., Prevezanos, D., Kouraklis, G. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214117 · Cited by 22

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)

Xiang, Z., Li, G., Mu, L., Wang, H., Zhou, C., Yan, H., & Huang, M. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231200320 · Cited by 22

Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial

Liang, H., Jiang, Y.-F., Liu, G., Wang, L., Wang, J., Lu, N., Xia, W., Ke, L., Ye, Y., Duan, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45126-0 · Cited by 24

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma

Zhao, L., Ren, Y., Zhang, G., Zheng, K., Wang, J., Sha, H., Zhao, M., Huang, R., Kang, D., Su, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008611 · Cited by 21

Efficacy and Safety of Nivolumab Plus Apatinib in Advanced Liver Carcinosarcoma: a Case Report

Zhao, L., Yang, Y., & Gao, Q. (2019) · Immunotherapy · doi:10.2217/imt-2018-0214 · Cited by 21

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Dyhl-Polk, A., Mikkelsen, M. K., Ladekarl, M. B., & Nielsen, D. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122662 · Cited by 21

Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer

Chen, J., Deng, S., Zhang, Y., Wang, C., Hu, X., Kong, D., Liang, G., Yuan, X., Li, Y., & Wang, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-805 · Cited by 21

Novel systemic therapy for hepatocellular carcinoma

Dong, Y., Liu, T., Yau, T. C. C., & Hsu, C. (2020) · Hepatology International · doi:10.1007/s12072-020-10073-7 · Cited by 20

Tumor Microenvironment Acidity Triggers Lipid Accumulation in Liver Cancer via SCD1 Activation

Ding, M., Zhang, S., Guo, Y., Yao, J., Shen, Q., Huang, M., Chen, W., Yu, S., Zheng, Y., Lin, Y., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0699 · Cited by 21

Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

Gao, G., Ni, J., Wang, Y., Ren, S., Liu, Z., Chen, G., Gu, K., Zang, A., Zhao, J., Guo, R., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-22 · Cited by 19

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

Han, J. W., & Jang, J. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411799 · Cited by 22

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Song, Y., Li, N., Li, Q., Liang, X., Zhang, S., Fan, Q., Yin, X., Zhuang, Z., Liu, Y., Zhang, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001279 · Cited by 20

Apatinib as an alternative therapy for advanced hepatocellular carcinoma

Zhang, X., Cao, M., Li, X., & Zhang, T. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i10.766 · Cited by 20

Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review

Tian, C., Yu, Y., Wang, Y., Yang, L., Tang, Y., Yu, C., Feng, G., Zheng, D., & Wang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352873 · Cited by 24

Recent advances and application of PD-1 blockade in sarcoma

Zuo, W., & Zhao, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s220045 · Cited by 20

Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma

Wang, T., Zhang, Q., Wang, N., Liu, Z., Zhang, B., & Zhao, Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201013162144 · Cited by 19

The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma

Wang, Y., Miao, X., Jiang, Y., Wu, Z., Zhu, X., Liu, H., Wu, X., Cai, J., Ding, X., & Gong, W. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04583-5 · Cited by 21

Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI)

Meng, M., Li, W., Yang, X., Huang, G., Wei, Z., Ni, Y., Han, X., Wang, J., & Ye, X. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_101_20 · Cited by 19

Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation

Song, G., Zhang, F., & Cheng, H. (2022) · Australasian Journal of Dermatology · doi:10.1111/ajd.13812 · Cited by 18

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial

Yang, C., Zhang, J., Zhang, Y., Ji, F., Chen, Y., Zhu, T., Zhang, L., Gao, H., Yang, M., Li, J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118053 · Cited by 20

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study

Li, X., Zhang, Q., Lu, Q., Cheng, Z., Liu, F., Han, Z., Yu, X., Yu, J., & Liang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023983 · Cited by 18

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review

Shen, J., & Wang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.934249 · Cited by 18

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Xu, J., Zhang, Y., Jia, R., Wang, Y., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Zou, J., & Wang, Q. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4075 · Cited by 24

Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial.

Zhao, H., Zhao, J., Jiang, L., Bi, X., Qian, H.-G., Du, S., Cai, J., Zhou, J., Li, Z., Liu, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.285 · Cited by 3

724P Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial

Zhao, H.-Y., Du, S., Zhu, Z., Jiang, L., Che, X., Qian, H., Song, J., Liu, D., Zhang, Y., Zhang, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.848 · Cited by 2

Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib

Zhang, Z., Zhou, Y., Hu, K., Li, Z., Wang, Z., & Huang, Y. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.07.005 · Cited by 9

A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection

Yan, S., Zhang, Y., Bi, X., Zhao, J., Du, S., Huang, Z., Zhang, Y., Liu, D., Li, Z., Zhou, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz438.022